Vertex Pharmaceuticals Stock Drops as Costs Surge
Vertex Pharmaceuticals (VRTX) saw its stock decline on Tuesday following reports from biotech companies revealing results that were worse than anticipated due to rising costs.
In the first quarter, Vertex reported adjusted earnings of $4.06 per share, which is a modest increase of 3% compared to the previous year, totaling $2.77 billion. However, analysts had expected earnings of $4.19 per share with revenue of $2.83 billion.
U.S. revenues climbed 9% to $1.66 billion, driven by higher prices. Conversely, the company’s international revenue suffered, particularly a 5% drop in Russia, totaling $11.1 billion, as the firm noted an “intellectual property violation.”
Total costs surged nearly 40% to $2.14 billion, attributed to ongoing R&D investments for various clinical development programs, along with costs linked to a $379 million impairment charge for the diabetes treatment VX-264, which will not move forward.
Vertex has raised its lower end of the annual revenue guidance from $11.75 billion to $11.85 billion, anticipating continued demand for cystic fibrosis drugs like the new Alyftrek. The upper forecast remains unchanged at $12 billion.
Recently, Vertex shares have dropped by 11%. Despite this, they have still risen by 10% since the start of 2025.
DoorDash Shares Fall After Revenue Disappointment, Acquisition News
Shares of DoorDash plunged on Tuesday after the food delivery service reported first-quarter revenues that missed analysts’ expectations.
The company announced its acquisition of the UK-based Deliveroo for nearly $4 billion, along with the restaurant reservation platform Sevenrooms for $1.2 billion. Interestingly, DoorDash moved its earnings announcement to before the market opens on Tuesday instead of the previously scheduled time.
For the first quarter, DoorDash recorded revenues of $3.03 billion, falling short of the anticipated $3.1 billion. However, earnings per share of $0.44 were slightly better than the expected $0.39.
Looking ahead to the second quarter, DoorDash adjusts its EBITDA guidance to market values of orders between $23.3 billion and $23.7 billion, with expectations of $600 million to $650 million. Analysts anticipated $23.5 billion and $633.1 million, respectively.
DoorDash shares fell more than 8% in early trading, though they remain up 12% year-to-date, outpacing the S&P 500.
Future of Corporate Profits Under Scrutiny
Market analysts are cautioning that investors might be overlooking potential challenges ahead.
Last week’s solid revenue reports contributed to the S&P 500 experiencing its longest winning streak in two decades. Current growth has surpassed expectations, with Deutsche Bank noting a record increase in share buybacks as a sign of strength.
Despite uncertainties surrounding President Trump’s tariff policies, corporate America appears to maintain a strong outlook. But Deutsche Bank’s analysts have slightly downgraded revenue expectations for this quarter by 2.6%.
It’s worth noting, though, that many businesses are either not considering the effects of tariffs in their guidance or are hesitant to adjust forecasts amid uncertainty. This caution could indicate potential vulnerabilities in consensus revenue estimates.
Palantir Technologies Stock Takes a Hit Post-Earnings
Palantir Technologies (PLTR) raised its annual outlook yet still disappointed investors with quarterly results, leading to a significant drop in the stock before the market opened on Tuesday.
The company posted first-quarter revenues of $884 million, a 39% year-over-year increase that exceeded analyst expectations. Earnings per share adjusted to 13 cents compared to 8 cents per share a year ago. Investors might have anticipated even more from this promising AI-centered firm.
Palantir shares have surged 64% since the year began and saw a more than fivefold increase over the past 12 months, largely due to optimism regarding software development aiding government efficiency and federal initiatives.
However, after reaching a peak in mid-February, the stock has faced some pressure. It’s currently anticipated to continue retreating from critical technical levels, possibly forming a double-top pattern.
Key support levels to watch for Palantir are at $97, $83, and $66, while significant resistance appears near $125.
The stock fell about 8% to around $114 in early trading.
Major Stock Futures Point to Lower Openings
Futures linked to the Dow Jones industrial average dropped by 0.7%.
S&P 500 futures decreased by 0.9%.
Meanwhile, Nasdaq 100 futures fell 1.1%.
